MAGGIC Risk Calculator for Heart Failure
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years
حداقل ۱۰ — حداکثر ۸۰ • واحد: %
حداقل ۰.۳ — حداکثر ۱۵ • واحد: mg/dL
حداقل ۶۰ — حداکثر ۲۵۰ • واحد: mmHg
حداقل ۱۰ — حداکثر ۶۰ • واحد: kg/m²
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–15
- Intermediate Risk16–25
- High Risk26–35
- Very High Risk36–50
The MAGGIC Risk Calculator for Heart Failure calculates stratifying cardiovascular risk, predicting thromboembolic events, or guiding therapeutic interventions. Key inputs include age. Scores guide initiating guideline-directed medical therapy, antithrombotic or anticoagulant regimens, or urgent coronary angiography. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Estimates 1- and 3-year mortality in heart failure patients
Clinical Indication
The MAGGIC Risk Calculator for Heart Failure is indicated for bedside clinical practice to support Estimates 1- and 3-year mortality in heart failure patients. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.
Limitations & Contraindications
In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.
Clinical Pearls & Action Plan
Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines.
Complex integer scoring system based on 13 predictors: age, gender, EF, NYHA class, creatinine, systolic BP, BMI, diabetes, COPD, smoking, HF duration, beta-blocker use, ACE-I/ARB use
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Patient age in years(years) |
| gender | string | Yes | Patient gender |
| ejection_fraction | integer | Yes | Left ventricular ejection fraction(%) |
| nyha_class | string | Yes | NYHA functional class |
| creatinine | float | Yes | Serum creatinine level(mg/dL) |
| systolic_bp | integer | Yes | Systolic blood pressure(mmHg) |
| bmi | float | Yes | Body mass index(kg/m²) |
| diabetes | string | Yes | Diabetes mellitus present |
| copd | string | Yes | Chronic obstructive pulmonary disease present |
| current_smoker | string | Yes | Current smoking status |
| hf_duration_over_18_months | string | Yes | Heart failure diagnosed >18 months ago |
| beta_blocker | string | Yes | Currently prescribed beta-blocker |
| ace_arb | string | Yes | Currently prescribed ACE inhibitor or ARB |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–15 | Low Risk | Low mortality risk |
| 16–25 | Intermediate Risk | Intermediate mortality risk |
| 26–35 | High Risk | High mortality risk |
| 36–50 | Very High Risk | Very high mortality risk |
Evidence-Based References (EBM)
- Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013 May;34(19):1404-13. doi: 10.1093/eurheartj/ehs337.DOI: 10.1093/eurheartj/ehs337
- Sartipy U, Dahlström U, Edner M, Lund LH. Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51,043 patients from the Swedish heart failure registry. Eur J Heart Fail. 2014 Feb;16(2):173-9. doi: 10.1111/ejhf.32.DOI: 10.1111/ejhf.32
- Simpson J, Jhund PS, Silva Cardoso J, Martinez F, Mosterd A, Ramires F, et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015 Nov 10;66(19):2059-71. doi: 10.1016/j.jacc.2015.08.878.DOI: 10.1016/j.jacc.2015.08.878